A Phase 2 interventional study of IMG-007 and Placebo in Atopic Dermatitis, Atopic Dermatitis Eczema and Eczema, sponsored by Inmagene LLC. Recruiting at 30 sites in 4 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Inmagene LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 80th largest by planned enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 202 in phase 2, reaches primary completion later than 68 of the 115 other live ones, and was the 595th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 41 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 405 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
Inmagene LLC is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Inmagene LLC has 3 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 48 weeks.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection as per protocol.
Drug: IMG-007
Subcutaneous injection as per protocol.
Drug: IMG-007
Subcutaneous injection as per protocol.
Drug: IMG-007
Subcutaneous injection as per protocol.
Drug: IMG-007
Subcutaneous injection as per protocol.
Drug: IMG-007
Subcutaneous injection as per protocol.
Drug: IMG-007
Subcutaneous injection as per protocol.
Drug: IMG-007
Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.
Drug: IMG-007 · Drug: Placebo
Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol.
Drug: IMG-007 · Drug: Placebo
Participants will receive IMG-007 subcutaneously.
Participants will receive a placebo subcutaneously.
Mean percent change from baseline in EASI at Week 24
Time frame: Baseline, Week 24
Proportion of participants achieving a vIGA-AD score of 0 (clear) or 1 (almost clear) and a ≥ 2-point reduction from baseline at Week 24
Time frame: Baseline, Week 24
Proportion of participants achieving a ≥ 75% reduction in EASI (EASI-75) at Week 24
Time frame: Baseline, Week 24
Proportion of participants achieving a ≥ 90% reduction in EASI (EASI-90) at Week 24
Time frame: Baseline, Week 24
Incidence and severity of TEAE including treatment-emergent SAEs
Time frame: Baseline, End of Study
Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 30 months is above that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IMG-007
Inmagene LLC